Andrea Califano

Columbia University Irving Medical Center

Full Professor(heuristic)

Bioinformatics and Genomic Networks · Molecular Biology

h-index96

i10-index235

Publications1,073

Citations55,095

Grants

34 total · 12 active

NIH #5R35CA197745-11

Predicting Cancer Cell Response to Endogenous and Exogenous Perturbations at the Single Cell Level

Active

Amount: $979K
Period: 2015-08-14 → 2029-07-31
PIs: 1
Est. capacity / PI: ~3 students

Awarded at COLUMBIA UNIVERSITY HEALTH SCIENCES

NIH #5R35CA197745-10

Predicting Cancer Cell Response to Endogenous and Exogenous Perturbations at the Single Cell Level

Active

Amount: $937K
Period: 2015-08-14 → 2029-07-31
PIs: 1
Est. capacity / PI: ~3 students

Awarded at COLUMBIA UNIVERSITY HEALTH SCIENCES

NIH #5R35CA197745-09

Predicting Cancer Cell Response to Endogenous and Exogenous Perturbations at the Single Cell Level

Active

Amount: $957K
Period: 2015-08-14 → 2029-07-31
PIs: 1
Est. capacity / PI: ~3 students

Awarded at COLUMBIA UNIVERSITY HEALTH SCIENCES

Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.

Lab Funding Health

Find elsewhere

Institution / lab homepage Search on ResearchGate

In-Field Influence

0.0008

PageRank within Molecular Biology co-authorship network

Explore collaboration map

Admission Signals

New preprint: Combinatorial Targeting of Avapritinib-Driven MAP Kinase Activation in High-Grade Glioma2026-06-24
New paper: Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTO (JCO Precision Oncology)2026-06-01
New NIH award: $500K — Drug Mechanism of Action-based targeting of tumor subpopulations2023-09-19
New NIH award: $1,736K — Center for Cancer Systems Therapeutics (CaST)2023-09-19
New NIH award: $164K — Studying the evolution of drug resistance in prostate cancer at the single cell level2023-09-19
New NIH award: $54K — Administrative Core2023-09-19
New NIH award: $968K — Elucidating and Targeting tumor dependencies and drug resistance determinants at the single cell level2022-09-21
New NIH award: $926K — Elucidating and Targeting tumor dependencies and drug resistance determinants at the single cell level2022-09-21
New NIH award: $956K — Elucidating and Targeting tumor dependencies and drug resistance determinants at the single cell level2022-09-21
New NIH award: $991K — Elucidating and Targeting tumor dependencies and drug resistance determinants at the single cell level2022-09-21

Data Freshness

Publications as of 2026-07-01
Grants as of 2026-06-30

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

ORCID: 0000-0003-4742-3679

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 119

Combinatorial Targeting of Avapritinib-Driven MAP Kinase Activation in High-Grade GliomaPreprint
Research Square · 2026-06-24
Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTO
JCO Precision Oncology · 2026-06-01
Abstract 6859: Targeting master regulators to reprogram neutrophils and enhance PD-1 blockade efficacy in castration-resistant prostate cancer.
Cancer Research · 2026-04-03
Abstract 3084: Network-based discovery of tumor-checkpoint inverter drugs targeting pancreatic ductal adenocarcinoma cell states and macrophage reprogramming
Cancer Research · 2026-04-03
Abstract 6858: Single-cell elucidation of molecularly distinct states and therapeutic vulnerabilities in IDH-mutant glioma.
Cancer Research · 2026-04-03
Abstract 1490: A single cell-based protein activity landscape for human small cell lung cancer
Cancer Research · 2026-04-03
Abstract 6759: High-throughput drug screening and single-cell network analysis identify rational combination therapies in IDH-mutant glioma
Cancer Research · 2026-04-03
Abstract 4938: Elucidation and pharmacologic targeting of master regulator proteins representing mechanistic determinants of macrophage state and immunoevasive potential
Cancer Research · 2026-04-03
Exon inclusion signatures enable accurate estimation of splicing factor activity
Nature Communications · 2026-03-12 · 1 citations
Abstract A017: RAS inhibition and cytotoxic chemotherapy target complementary cell states in pancreatic cancer
Cancer Research · 2026-03-05
TMPO promotes cellular dissemination and metastasis in circulating tumor cells
bioRxiv (Cold Spring Harbor Laboratory) · 2025-12-27
Table S6 from OncoLoop: A Network-Based Precision Cancer Medicine Framework
2025-12-11
Table S1 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies
2025-12-11
Table S7 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies
2025-12-11
Table S1 from OncoLoop: A Network-Based Precision Cancer Medicine Framework
2025-12-11
Table S3 from OncoLoop: A Network-Based Precision Cancer Medicine Framework
2025-12-11
Table S4 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies
2025-12-11
Supplementary Figures S1-S6 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies
2025-12-11
Supplementary Figures S1-S11 from OncoLoop: A Network-Based Precision Cancer Medicine Framework
2025-12-11
Table S5 from OncoLoop: A Network-Based Precision Cancer Medicine Framework
2025-12-11

Open author page on OpenAlex →